### Summary: Engineered CD40 Agonist Antibody Induces Systemic Tumor Regression in Phase 1 Trial A groundbreaking phase 1 clinical trial has demonstrated the potential of an engineered CD40 agonist antibody, 2141-V11, to elicit robust systemic anti-tumor responses with minimal toxicity. Developed by researchers at Rockefeller University, this modified antibody addresses longstanding limitations of traditional CD40…

### Summary: Ketogenic Diet Enhances Exercise Benefits in Hyperglycemic Models A recent study published in *Nature Communications* on February 25, led by exercise medicine researcher Sarah Lessard from the Fralin Biomedical Research Institute at Virginia Tech, explores how dietary interventions can augment the physiological benefits of exercise in individuals with hyperglycemia. Hyperglycemia, a hallmark of…

### Accuracy of Allergy Forecasts: Implications for Clinical Practice Allergy forecasts, commonly available on websites and apps, aim to help patients manage symptoms by predicting pollen levels, but their reliability is often questionable. Pollen counts, as reported by organizations like the National Allergy Bureau (NAB) under the American Academy of Allergy, Asthma & Immunology (AAAAI),…